© 2023 MJH Life Sciences™ and Managed Healthcare Executive. All rights reserved.
Type II Inflammation
Patients With Moderate-to-Severe Atopic Dermatitis Experience Impaired QOL, Feel Disease Burden
September 07, 2022
A national study in Germany identified the baseline characteristics of patients with moderate-to-severe atopic dermatitis (AD) to understand how they are usually treated with Dupixent in the real world.
Management of EoE May Need to Be Rethought to Reduce Treatment Burden, Impact on Quality of Life
September 02, 2022
Therapeutic goals of reducing eosinophil counts below a certain level in eosinophilic esophagitis (EoE) has a marginal benefit for the impact on quality of life and treatment burden.
Patients Maintain Controlled AD Even After Reduction of Dupixent Dose
August 10, 2022
Patients with persistently controlled atopic dermatitis (AD) who had their doses reduced were able to maintain their low disease activity.
Overlap of Upper Airway Diseases Increases Risk of Outpatient Visit Burden
August 09, 2022
Patients with chronic rhinosinusitis with nasal polyps had the greatest number of outpatient visits and the shortest time between visits.
Coping Strategies Related to Perception of Health-Related Quality of Life in EoE
August 02, 2022
Less-effective coping strategies, such as passive and palliative reaction, were associated with a significant impact on health-related quality of life in eosinophilic esophagitis (EoE).
Patients on Dupixent Experience Temporary Increase in Eosinophil Levels
July 07, 2022
The increases had no impact on the efficacy of the drug and were rarely associated with symptoms or sequelae.
HRQOL Declined in Certain Areas for Patients With AD During the Pandemic
June 24, 2022
Certain problems such as pain/discomfort, worrying and fear of the persistence/recurrence of atopic dermatitis (AD) became more common among patients with AD since the start of the COVID-19 pandemic.
FDA Expands Approval of Dupixent to Children 6 Months and Older With Moderate-to-Severe Atopic Dermatitis
June 10, 2022
Dupixent was already approved for patients 6 years and older. The new approval makes the drug available to children 6 months to 5 years whose atopic dermatitis is inadequately controlled.
Dupixent Safe, Effective Over 52 Weeks in Adolescents With Moderate-to-Severe AD
June 01, 2022
A 52-week open-label extension study supported the long-term use of Dupixent to treat adolescents with moderate-to-severe atopic dermatitis.
Real-World Evidence Corroborates Dupixent Clinical Trials in Atopic Dermatitis
May 25, 2022
Data gathered from electronic medical records found that the results in a real-world patient population with atopic dermatitis were consistent with those found in clinical trials.